Big Money Sentiment increased to 1.71 in Q3 2018. It has change of 0.49, from 2018Q2’s 1.22. The ratio is positive due to AcelRx Pharmaceuticals, Inc. positioning: 9 sold and 8 reduced. 12 funds amassed stakes and 17 increased stakes. Investors holded 4.49 million in 2018Q2 but now own 6.40 million shares or 42.63% more.
Wells Fargo Company Mn invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Granite Investment Prtn Lc owns 53,853 shs for 0.01% of their capital. Morgan Stanley owns 42,521 shs. 50,879 were accumulated by Goldman Sachs. Raymond James & Assocs invested in 15,000 shs. Gsa Prtnrs Ltd Liability Partnership owns 0.03% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 120,158 shs. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Virtu Fin Ltd Liability reported 0% stake. Renaissance Technologies Ltd Liability accumulated 428,700 shs. Bridgeway has invested 0.01% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Bluecrest Cap Management Ltd invested in 12,900 shs. One Trading Lp invested in 0% or 14,545 shs. Joel Isaacson And Com Ltd Liability Corp holds 0.01% or 20,000 shs. Moreover, Da Davidson And has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 67,500 shs. Jpmorgan Chase And stated it has 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).

AcelRx Pharmaceuticals, Inc. had 3 selling transactions and 6 insider purchases since September 24, 2018. This’s net activity of $22,185. ASADORIAN RAFFI also bought $15,646 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Tuesday, November 13. 28,351 shs were sold by Dasu Badri N, worth $141,755. On Thursday, November 15 Shares for $58,376 were bought by EDWARDS MARK G. 6,953 shs valued at $31,289 were sold by Hamel Lawrence G on Monday, September 24. Shares for $49,120 were bought by Palmer Pamela P on Monday, November 19.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

In total 3 analysts cover AcelRx Pharmaceuticals (NASDAQ:ACRX). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:ACRX)’s analyst reports since August 16, 2018 according to StockzIntelligence Inc. On Wednesday, October 10 the firm earned “Buy” rating by Ladenburg Thalmann. The company rating was upgraded by Jefferies on Monday, October 15. Listed here are AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) PTs and latest ratings.

23/10/2018 Broker: FBR Capital Rating: Buy New Target: $9 Initiates Coverage On
15/10/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy New Target: $8 Upgrade
10/10/2018 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Buy Old Target: $7 New Target: $10 Maintain
16/08/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $7 Initiates Coverage On

The stock increased 0.58% or $0.015 during the last trading session, hitting $2.585.AcelRx Pharmaceuticals, Inc. has volume of 656,970 shares. Since February 13, 2018 ACRX has risen 48.44% and is uptrending. ACRX outperformed by 48.44% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The company has $197.48 million market cap. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Currently it has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news posted briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “AcelRx Pharmaceuticals prices public offering of common stock – Seeking Alpha” posted on November 12, 2018, “AcelRx’s DSUVIA Was Just Approved And The Stock Is Primed For A Sharp Upward Move – Seeking Alpha” on November 08, 2018, “Hopes Are High For AcelRx After Dsuvia Approval – Will Price Follow? – Seeking Alpha” with a publish date: November 05, 2018, “AcelRx Provides Encouraging Q2 Update – Seeking Alpha” and the last “FDA Ad Com backs AcelRx Pharma’s Dsuvia – Seeking Alpha” with publication date: October 12, 2018.